Factors associated with the risk of secondary progression in multiple sclerosis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Multiple Sclerosis

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458508089361PMID 18573840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictors of relapse rate in MS clinical trials

  2008cited by this paper
• New natural history of interferon-beta-treated relapsing multiple sclerosis.

  2007cited by this paper
• Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis

  2007influential reference
• Progression in multiple sclerosis: further evidence of an age dependent process.

  2007influential reference
• Age at onset determines the occurrence of the progressive phase of multiple sclerosis

  2007influential reference
• New natural history of interferon‐β–treated relapsing multiple sclerosis

  2007cited by this paper
• The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

  2006cited by this paper
• Predictors of relapse rate in MS clinical trials

  2005cited by this paper
• The Age-Related Decrease in CNS Remyelination Efficiency Is Attributable to an Impairment of Both Oligodendrocyte Progenitor Recruitment and Differentiation

  2002cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

  1998cited by this paper
• Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

  1998cited by this paper
• Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

  1998cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Natural history of multiple sclerosis

  1994cited by this paper
• Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients

  1989cited by this paper
• Multiple sclerosis

  1988cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Study Group

  1971influential reference

• Did COVID‐19 Pandemic Change the Course of Multiple Sclerosis? A Retrospective Eight‐Year Study

  2025cites this paper
• Predictive factors for the progression of multiple sclerosis: a meta-analysis

  2025cites this paper
• Predictors of progression of multiple sclerosis in a sample of Egyptian patients

  2023influential citation
• Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

  2023cites this paper
• How does Nogo receptor influence demyelination and remyelination in the context of multiple sclerosis?

  2023cites this paper
• Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.

  2022cites this paper
• Sex differences regulate immune responses in experimental autoimmune encephalomyelitis and multiple sclerosis

  2021cites this paper
• Determinants of disability development in patients with multiple sclerosis

  2020cites this paper
• Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

  2020cites this paper
• The genetics of multiple sclerosis in the Northern Isles of Scotland

  2020cites this paper
• Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors

  2020cites this paper
• An argument for broad use of high efficacy treatments in early multiple sclerosis

  2019cites this paper
• Risk of secondary progressive multiple sclerosis: A longitudinal study

  2019cites this paper
• Fine Motor Skills and the Occupations of Young Adults with Multiple Sclerosis

  2018cites this paper
• Predicting risk of secondary progression in multiple sclerosis: A nomogram

  2018cites this paper
• Can a stress management programme reduce stress and improve quality of life in people diagnosed with multiple sclerosis?

  2018cites this paper
• MicroRNA profiling of multiple sclerosis: from brain to blood

  2017cites this paper
• Disability Progression in Multiple Sclerosis Is Affected by the Emergence of Comorbid Arterial Hypertension

  2016influential citation
• Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis

  2016cites this paper
• Variations of Multiple Sclerosis Lesions on MRI and their Cognitive Effect

  2016cites this paper
• Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

  2015cites this paper
• Epidemiology of Progressive Multiple Sclerosis

  2013cites this paper
• Investigation of cytocrom c oxidase gene subunits expression on the Multiple sclerosis

  2013cites this paper
• Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis

  2013cites this paper
• Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis

  2013cites this paper
• Разработка компьютерного модуля для прогнозирования и оценки эффективности базисной терапии рассеянного склероза

  2012influential citation
• Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique

  2012cites this paper
• COX5B and COX2 gene expressions in Multiple Sclerosis

  2012cites this paper
• Multiple sclerosis: an overview

  2012cites this paper
• Identification of pathogenic autoantibody responses in multiple sclerosis

  2011cites this paper
• Gender Issues in Multiple Sclerosis: An Update

  2010cites this paper
• Multiple sclerosis : understanding a complex neurological condition.

  2010cites this paper
• The natural history of secondary progressive multiple sclerosis

  2010cites this paper
• A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.

  2010cites this paper
• New perspectives in the natural history of multiple sclerosis

  2010cites this paper
• SEX DIFFERENCES IN MULTIPLE SCLEROSIS

  2010cites this paper
• Parity and secondary progression in multiple sclerosis

  2009cites this paper
• Long-term effects of childbirth in MS

  2009cites this paper